文献速递免疫规划传染病防控与疫情报告

日本Omicron变异株流行期间加强接种后SARS-CoV-2抗体滴度的动力学

Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan.
PubMed 文献 · Vaccine · 2024-07-31

本研究在日本备前市开展前瞻性队列研究,纳入424名至少接种三剂COVID-19疫苗的≥18岁居民和工作人员,于2023年11月至2024年1月采集静脉血,共821次抗体测量。采用混合效应模型分析log转换的S-RBD IgG抗体滴度动力学,发现抗体滴度随时间下降但随加强接种次数增加而升高,既往感染者抗体滴度更高且下降更缓慢。

要点

  • 抗体滴度随时间下降,但加强接种(尤其是Omicron及XBB.1.5适配疫苗)可提高滴度。
  • 既往感染者抗体滴度高于未感染者,且随时间下降更缓慢(交互项系数0.006,95%CI 0.001至0.011)。
  • 不同疫苗产品加强后抗体滴度变化系数不同,如Moderna Omicron适配疫苗0.279(95%CI 0.012至0.546)。

核心结论

  • 研究提供了日本高接种率人群中加强接种后(包括XBB.1.5适配疫苗)抗体动力学的具体数据,结果强调在优化疫苗接种策略时需考虑个体人口学特征和既往感染史。

研究设计与样本

  • 前瞻性队列研究,于2023年11月至2024年1月在日本备前市开展,纳入424名至少接种三剂COVID-19疫苗的≥18岁居民和工作人员,共进行821次抗体测量,采用混合效应模型分析log转换的S-RBD抗体滴度。

主要发现

  • S-RBD抗体滴度随时间下降,但随加强接种次数增加而升高,尤其是Omicron及其亚型XBB.1.5适配疫苗:辉瑞-BioNTech Omicron适配疫苗系数0.156(95%CI -0.032至0.344),辉瑞-BioNTech XBB适配疫苗系数0.226(95%CI -0.051至0.504),Moderna Omicron适配疫苗系数0.279(95%CI 0.012至0.546),Moderna XBB适配疫苗系数0.338(95%CI -0.052至0.728)。
  • 既往感染者维持更高的抗体滴度,且与未感染者相比下降更缓慢(与时间交互项系数0.006;95%CI 0.001至0.011)。
  • 采用广义估计方程和区间删失随机截距模型的敏感性分析证实了这些发现的稳健性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the emergence of SARS-CoV-2 variants and waning immunity after initial vaccination, data on antibody kinetics following booster doses, particularly those adapted to Omicron subvariants like XBB.1.5, remain limited. This study assesses the kinetics of anti-spike protein receptor-binding domain (S-RBD) IgG antibody titers post-booster vaccination in a Japanese population during the Omicron variant epidemic. METHODS: A prospective cohort study was conducted in Bizen City, Japan, from November 2023 to January 2024. Participants included residents and workers aged ≥18 years, with at least three COVID-19 vaccinations. Antibody levels were measured from venous blood samples. The study analyzed 424 participants and 821 antibody measurements, adjusting for variables such as age, sex, underlying conditions, and prior infection status. Mixed-effects models were employed to describe the kinetics of log-transformed S-RBD antibody titers. RESULTS: The study found that S-RBD antibody titers declined over time but increased with the number of booster vaccinations, particularly those adapted to Omicron and its subvariant XBB.1.5 (Pfizer-BioNTech Omicron-compatible: 0.156, 95%CI -0.032 to 0.344; Pfizer-BioNTech XBB-compatible: 0.226; 95%CI -0.051 to 0.504; Moderna Omicron-compatible: 0.279, 95%CI 0.012 to 0.546; and Moderna XBB-compatible: 0.338, 95%CI -0.052 to 0.728). Previously infected individuals maintained higher antibody titers, which declined more gradually compared to uninfected individuals (coefficient for interaction with time 0.006; 95%CI 0.001 to 0.011). Sensitivity analyses using Generalized Estimating Equations and interval-censored random intercept model confirmed the robustness of these findings. CONCLUSIONS: The study provides specific data on antibody kinetics post-booster vaccination, including the XBB.1.5-adapted vaccine, in a highly vaccinated Japanese population. The results highlight the importance of considering individual demographics and prior infection history in optimizing vaccination strategies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Matsumoto N, Sasaki A, Kadowaki T, et al. Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan. Vaccine. 2024. PMID: 39088986. doi:10.1016/j.vaccine.2024.126156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。